Newsbenzinga
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
· Published
Article summary
Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.
An excerpt from the original article.
Comments —
Loading comments…